Artificial Intelligence (AI) is fast becoming an integral component of several FDA-regulated products, a shift that has led to the clearances and approvals of hundreds of such products. Recognizing the challenges these new technologies present to both the regulatory body and industry, the FDA has recently stepped up its game.
In a bid to provide a comprehensive guide on how FDA-regulated products interact with AI, the FDA has made significant moves. These include recently publishing two key communications. One focuses on medical devices, and the other zeroes in on drug manufacturing, both of which are fields in which AI is rapidly encroaching.
These FDA responses are a clear demonstration of the authority’s commitment to keeping abreast of AI’s swift advance. Specifically, one objective has been to understand the issues that might arise when AI becomes an integral component in domains it has traditionally supervised.
The community of legal professionals will further explore these themes in an upcoming complimentary webinar. AGG Technology chair Lori L. Wright and AGG Food & Drug attorney Laura S. Dona will examine intricacies in these FDA responses and shed light on the regulatory framework’s possible future directions.
The webinar promises to be a valuable discourse for all parties. It offers an opportunity for legal practitioners and industry professionals to gain insights that could prove vital in navigating the evolving landscape of FDA regulation as it intersects with AI.
FDA’s effort to adapt to AI’s rapidly advancing frontier is significant. It’s a response that hints at the profound influence AI promises to wield on regulatory frameworks worldwide. And it’s yet another testament to the transformative power of Artificial Intelligence.